Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective oestrogen receptor modulators.

H G Burger1

  • 1Prince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Vic., Australia.

Hormone Research
|September 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risks and benefits of hormone therapy: has medical dogma now been overturned?

Climacteric : the journal of the International Menopause Society·2014
Same author

The stages of reproductive aging as proposed by workshops held in 2001 and 2010 (STRAW and STRAW + 10): a commentary.

Climacteric : the journal of the International Menopause Society·2013
Same author

Evidence-based assessment of the impact of the WHI on women's health.

Climacteric : the journal of the International Menopause Society·2012
Same author

Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat.

Maturitas·2009
Same author

Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause.

Best practice & research. Clinical obstetrics & gynaecology·2008
Same author

Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men.

The Journal of clinical endocrinology and metabolism·2007
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

Selective estrogen receptor modulators (SERMs) offer tissue-specific effects, acting as estrogen agonists in some tissues and antagonists in others. Raloxifene, a second-generation SERM, demonstrates anti-fracture efficacy and reduces breast cancer incidence, with varying effects on lipids and coagulation.

Area of Science:

  • Endocrine pharmacology
  • Molecular endocrinology
  • Drug discovery

Background:

  • Selective estrogen receptor modulators (SERMs) exhibit tissue-specific estrogenic effects, acting as agonists in some tissues and antagonists in others.
  • Tamoxifen, a first-generation SERM, showed estrogen-like activity on bone and antagonist effects on breast tissue, but also unwanted endometrial stimulation.
  • Raloxifene, a second-generation SERM, demonstrates beneficial effects on bone, lipids, and coagulation, alongside antagonist effects on breast and uterus.

Purpose of the Study:

  • To review the efficacy and safety profile of raloxifene, a second-generation SERM.
  • To explore the mechanisms underlying the tissue-specific actions of SERMs.
  • To discuss the potential of SERMs as a prototype for other selective steroid receptor modulators.

Related Experiment Videos

Main Methods:

  • Review of prospective, placebo-controlled, randomized trial data for raloxifene.
  • Analysis of structural and molecular mechanisms of estrogen receptor (ER) ligand interactions.
  • Comparison of SERM effects with estrogen and placebo across different target tissues.

Main Results:

  • Raloxifene demonstrated anti-fracture efficacy (vertebral fractures) and significantly reduced new breast cancer incidence.
  • Raloxifene showed neutral uterine effects, increased venous thromboembolism risk similar to estrogen, and favorable lipid profiles (except HDL).
  • Preliminary data on cardiovascular events and cognitive function are reassuring.

Conclusions:

  • SERMs like raloxifene represent a significant advance in developing tissue-specific endocrine therapies.
  • Understanding SERM mechanisms involves ligand-induced ER conformational changes and co-regulator recruitment.
  • SERMs may pave the way for novel selective modulators targeting other steroid receptors.